Document Detail

Review article: remission rates achievable by current therapies for inflammatory bowel disease.
MedLine Citation:
PMID:  21323689     Owner:  NLM     Status:  Publisher    
Background  New medical therapies have improved outlook in inflammatory bowel disease but published impact on surgical rates has been modest suggesting that many patients are still not attaining remission. Aim  To review remission rates with current medical treatments for inflammatory bowel disease. Methods  We searched MEDLINE (source PUBMED, 1966 to January, 2011). Results  Induction and maintenance of remission was observed in 20% (range, 9-29.5%) and 53% (range, 36.8-59.6%) of ulcerative colitis (UC) patients treated with oral 5-ASA derivatives. Induction of remission was noted in 52% (range, 48-58%) of Crohn's disease (CD) patients and 54% of UC patients treated with steroids in population-based cohorts. Maintenance of remission was reported in 71% (range, 56-95%) of CD patients on azathioprine over a 6-month to 2-year period and in 60% (range, 41.7-82.4%) in UC at 1 year or longer. Induction and maintenance of remission was noted in 39% (range, 19.3-66.7%) and 70% (range, 39-90%) of CD patients on methotrexate over a 40-week period. Induction of remission was reported in 32% (range, 25-48%), 26% (range, 18-36%) and 20% (range, 19-23%) of CD patients on infliximab, adalimumab or certolizumab pegol, respectively. The corresponding figures were 45% (range, 39-59%), 43% (range, 40-47%) and 47.9% at weeks 20-30 among initial responders. Induction of remission was observed in 33% (range, 27.5-38.8%) and 18.5% of UC patients on infliximab or adalimumab, respectively. Maintenance of remission was noted in 33% (range, 25.6-36.9%) of UC patients on infliximab at week 30. Approximately one-fifth of CD and UC patients treated with biologicals require intestinal resection after 2-5 years in referral-centre studies. Conclusion  In the era of biologics, the proportion of patients with inflammatory bowel disease not entering remission remains high.
L Peyrin-Biroulet; M Lémann
Related Documents :
19940469 - Hypercoagulable state and methylenetetrahydrofolate reductase (mthfr) c677t mutation in...
18393149 - The phenotypic heterogeneity of severe hemophilia.
7589679 - Characteristics of blood hemostatic markers in a patient with ovarian hyperstimulation ...
18544429 - On-label versus off-label use of recombinant activated factor vii: a comprehensive revi...
17944999 - Activation of coagulation with concurrent impairment of anticoagulant mechanisms correl...
1984679 - Clinical pharmacokinetics of a placenta-derived factor xiii concentrate in type i and t...
8869219 - Time course of radiologic lesions in spinal hyperostosis: an osteoradiometric study.
8108539 - Aspiration in acute stroke: a clinical study with videofluoroscopy.
22455249 - Troponin-i positivity in patients referred to rapid access chest pain clinic.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-2-15
Journal Detail:
Title:  Alimentary pharmacology & therapeutics     Volume:  -     ISSN:  1365-2036     ISO Abbreviation:  -     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-2-17     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8707234     Medline TA:  Aliment Pharmacol Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2011 Blackwell Publishing Ltd.
Inserm U954 and Department of Hepato-Gastroenterology, University Hospital of Nancy, Henri Poincaré University, Vandœuvre-lès-Nancy, France. Department of Hepato-Gastroenterology, Hôpital Saint-Louis, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Randomised clinical trial: dried plums (prunes) vs. psyllium for constipation.
Next Document:  Individual placement and support - a model to get employed for people with mental illness - the firs...